English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

J Investig Allergol Clin Immunol 2019; Vol. 29(5): 378-398 © 2019 Esmon Publicidad as premedication in an attempt to reintroduce the drug with tolerance. A provocation test was programmed for 2 days to achieve a total dose of 1000 mg of abiraterone. The protocol on the first day comprised 50 mg, 150 mg, and 300 mg, with a 1-hour interval between doses and 2 hours of observation after the last dose (cumulative dose, 500 mg). Ten hours after the challenge was completed, the patient developed a pruriginous micropapular rash on the thorax, affecting the groins and the axillas (Supplementary Material, Photo). Once the Urology Department confirmed that abiraterone was the first‐choice agent for this patient, we developed a desensitization protocol (Table) in collaboration with the Pharmacy Department. Doses were prepared by weighing the corresponding amount of powder (10 mg, 30 mg, and 125 mg) and filling empty gelatine capsules. Dextrin maltose was used as the excipient. The desensitization protocol was stepped up every 3 days at the hospital, starting with the 10‐mg dose; the patient maintained the maximum tolerated dose at home (Table). We decided to premedicate the patient with ebastine 20 mg/24 h and prednisone 15 mg/12 h. Once the total dose was reached, ebastine was stopped, and prednisone was stepped down, continuing with 10 mg/12 h during the following 2 days and maintaining 5 mg/12 h, as per the summary of product characteristics of abiraterone. The patient did not experience any problems or adverse events during the protocol, which was fully tolerated. Allergic reactions to anticancer drugs are a growing problem in allergology clinics, and desensitization protocols are useful when the drug involved is a first‐choice option [3]. Rapid desensitization in IgE‐mediated reactions has well‐defined pathophysiological mechanisms, and while the procedure is risky, it has proven to be safe and efficacious [4]. In the case of late reactions (ie, more than 1 hour after administration), which are similar to those in the present case and are also frequently managed with rapid desensitization [5], there is no consensus on the ideal protocol, Safe and Successful Protocol for Desensitization to Abiraterone